JenaValve Technology, a Germany-based medical device company, has received CE mark approval for its second-generation transapical transcatheter aortic valve implantation (TAVI) system, designed to treat severe aortic valve stenosis in elderly high-risk patients.
The TAVI system incorporates both the Cathlete delivery system and the JenaValve heart valve prosthesis.
The approval is based on a 73-patient prospective multicentre uncontrolled clinical trial, which supported the safety and efficacy of the JenaValve system.
The primary endpoint of the trial was the 30-day mortality rate, while the secondary endpoints included the rate of successful implantation, as well as further parameters for performance and safety of the prosthetic heart valve.
Â
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
![](/wp-content/themes/goodlife-wp-B2B/assets/images/company-profile-unit.png)
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData